Segall Bryant & Hamill LLC Reduces Holdings in Pediatrix Medical Group, Inc. $MD

Segall Bryant & Hamill LLC reduced its stake in shares of Pediatrix Medical Group, Inc. (NYSE:MD) by 77.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 143,716 shares of the company’s stock after selling 504,961 shares during the period. Segall Bryant & Hamill LLC’s holdings in Pediatrix Medical Group were worth $2,407,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the stock. Smartleaf Asset Management LLC increased its position in Pediatrix Medical Group by 10.6% during the third quarter. Smartleaf Asset Management LLC now owns 6,250 shares of the company’s stock worth $101,000 after buying an additional 601 shares in the last quarter. PNC Financial Services Group Inc. boosted its stake in shares of Pediatrix Medical Group by 4.5% during the third quarter. PNC Financial Services Group Inc. now owns 14,525 shares of the company’s stock valued at $243,000 after acquiring an additional 631 shares during the last quarter. Amalgamated Bank increased its position in Pediatrix Medical Group by 3.5% during the 3rd quarter. Amalgamated Bank now owns 24,891 shares of the company’s stock worth $417,000 after purchasing an additional 831 shares in the last quarter. New York State Common Retirement Fund raised its stake in Pediatrix Medical Group by 1.7% in the 2nd quarter. New York State Common Retirement Fund now owns 62,245 shares of the company’s stock valued at $893,000 after purchasing an additional 1,034 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC raised its stake in Pediatrix Medical Group by 10.0% in the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 11,977 shares of the company’s stock valued at $201,000 after purchasing an additional 1,092 shares during the last quarter. Institutional investors and hedge funds own 97.71% of the company’s stock.

Pediatrix Medical Group Stock Down 3.0%

Shares of NYSE:MD opened at $19.29 on Friday. The firm has a market cap of $1.60 billion, a PE ratio of 9.94 and a beta of 0.79. The company has a fifty day simple moving average of $21.16 and a 200 day simple moving average of $19.88. The company has a current ratio of 1.66, a quick ratio of 1.66 and a debt-to-equity ratio of 0.66. Pediatrix Medical Group, Inc. has a 12-month low of $11.84 and a 12-month high of $24.99.

Pediatrix Medical Group (NYSE:MD) last posted its quarterly earnings data on Thursday, February 19th. The company reported $0.50 EPS for the quarter, missing analysts’ consensus estimates of $0.53 by ($0.03). The company had revenue of $493.77 million for the quarter, compared to the consensus estimate of $486.23 million. Pediatrix Medical Group had a net margin of 8.64% and a return on equity of 19.59%. The company’s revenue was down 1.7% compared to the same quarter last year. During the same quarter last year, the company earned $0.51 earnings per share. On average, equities research analysts anticipate that Pediatrix Medical Group, Inc. will post 1.38 EPS for the current fiscal year.

Insider Activity at Pediatrix Medical Group

In related news, CEO Mark S. Ordan sold 23,000 shares of Pediatrix Medical Group stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $22.41, for a total value of $515,430.00. Following the completion of the transaction, the chief executive officer directly owned 302,805 shares in the company, valued at approximately $6,785,860.05. This trade represents a 7.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.90% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently commented on MD. Zacks Research downgraded shares of Pediatrix Medical Group from a “strong-buy” rating to a “hold” rating in a report on Friday, January 23rd. Truist Financial lowered their target price on Pediatrix Medical Group from $24.00 to $21.00 and set a “hold” rating for the company in a research note on Thursday, February 19th. Deutsche Bank Aktiengesellschaft set a $19.00 price target on Pediatrix Medical Group in a research report on Friday, February 20th. UBS Group lowered their price objective on shares of Pediatrix Medical Group from $23.00 to $22.00 and set a “neutral” rating for the company in a research report on Tuesday, February 24th. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of Pediatrix Medical Group in a research note on Monday, December 29th. One research analyst has rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat, Pediatrix Medical Group presently has a consensus rating of “Hold” and a consensus target price of $19.80.

Pediatrix Medical Group Profile

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.